

Fabio Nascimbeni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2898395/fabio-nascimbeni-publications-by-year.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61 papers	3,294 citations	27 h-index	57 g-index
67 ext. papers	4,273 ext. citations	4.3 avg, IF	5.6 L-index

#	Paper	IF	Citations
61	Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations.. <i>Journal of the American Heart Association</i> , 2022 , e023668	6	2
60	Achilles tendon ultrasonography in familial hypercholesterolemia: A sub-study of the Lipid transPort disorders Italian GENetic Network (LIPIGEN). <i>Journal of Internal Medicine</i> , 2021 ,	10.8	1
59	A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2021 ,	1.6	2
58	The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease. <i>Liver International</i> , 2021 , 41, 224-225	7.9	1
57	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. <i>Diagnostics</i> , 2021 , 11,	3.8	22
56	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. <i>Internal and Emergency Medicine</i> , 2021 , 16, 281-308	3.7	21
55	Hyperferritinemia and diagnosis of type 1 Gaucher disease. <i>American Journal of Hematology</i> , 2020 , 95, 570-576	7.1	3
54	Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist. <i>Digestive and Liver Disease</i> , 2020 , 52, 368-373	3.3	8
53	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. <i>Digestive and Liver Disease</i> , 2020 , 52, 359-367	3.3	2
52	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020 , 72, 828-838	13.4	22
51	The clinical relevance of genetic variants of uncertain significance in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2020 , 315, e96-e97	3.1	
50	Lipoprotein(a) is significantly higher and associated with increased prevalence of atherosclerotic cardiovascular disease in mutation-negative familial hypercholesterolemia patients. <i>Atherosclerosis</i> , 2020 , 315, e142-e143	3.1	
49	Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. <i>Liver International</i> , 2020 , 40, 3061-3070	7.9	12
48	Looking for women in hepatology: Sex authorship differences in clinical practice guidelines and position statements. <i>Digestive and Liver Disease</i> , 2019 , 51, 911-913	3.3	2
47	A critical appraisal of the use of ultrasound in hepatic steatosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 667-681	4.2	23
46	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. <i>Hepatology</i> , 2019 , 70, 1457-1469	11.2	238
45	Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. <i>Atherosclerosis</i> , 2019 , 284, 66-74	3.1	31

44	Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?. <i>Digestive and Liver Disease</i> , 2019 , 51, 462-470	3.3	26
43	Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. <i>Future Medicinal Chemistry</i> , 2019 , 11, 2171-2192	4.1	18
42	A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?. <i>Acta Diabetologica</i> , 2019 , 56, 385-396	3.9	42
41	Is it time to include non-alcoholic fatty liver disease in the current risk scores for atrial fibrillation?. <i>Digestive and Liver Disease</i> , 2018 , 50, 626-628	3.3	4
40	Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2018 , 68, 74-80	2.1	23
39	Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?. <i>Diseases (Basel, Switzerland)</i> , 2018 , 6,	4.4	13
38	Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Thyroid</i> , 2018 , 28, 1270-1284	6.2	50
37	Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease. <i>Molecular Genetics and Metabolism</i> , 2018 , 125, 64-72	3.7	13
36	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 351-367	4.2	34
35	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. <i>Journal of Hepatology</i> , 2018 , 68, 335-352	13.4	298
34	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018 , 277, 413-418	3.1	35
33	Hypothyroidism and nonalcoholic fatty liver disease - a chance association?. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2018 , 41,	1.3	8
32	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017 , 49, 471-483	3.3	179
31	NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk. <i>Hepatology</i> , 2017 , 65, 2122-2123	11.2	2
30	Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. <i>Metabolism: Clinical and Experimental</i> , 2017 , 72, 57-65	12.7	80
29	NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. <i>Advances in Therapy</i> , 2017 , 34, 1291-1326	4.1	232
28	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017 , 29, 11-16	1.7	38
27	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017 , 29, 17-24	1.7	45

26	Nonalcoholic fatty liver disease: Evolving paradigms. <i>World Journal of Gastroenterology</i> , 2017 , 23, 6571-6592	5.92	92
25	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2017 , 23, 1458-1468	5.6	26
24	Noninvasive diagnosis of nonalcoholic fatty liver disease, is the more expensive the better?. <i>AME Medical Journal</i> , 2017 , 2, 171-171	1	1
23	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016 , 3, e000075	3.9	62
22	The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. <i>Advances in Therapy</i> , 2016 , 33, 291-319	4.1	54
21	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 333-42	3.3	42
20	Hepatic and Extrahepatic Malignancies in NAFLD 2016 , 271-290		
19	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 355	6.3	30
18	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. <i>World Journal of Gastroenterology</i> , 2016 , 22, 9674-9693	5.6	69
17	The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. <i>Hepatology</i> , 2016 , 62, 1071-1087	5.1	82
16	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 936-44	4	378
15	Alcohol and Steatosis: The Japanese Paradox. <i>EBioMedicine</i> , 2016 , 8, 23-24	8.8	1
14	Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy. <i>Digestive and Liver Disease</i> , 2016 , 48, 1399-1401	3.3	6
13	Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 763-71.e1-6	6.9	46
12	Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. <i>Liver International</i> , 2015 , 35, 2340-1	7.9	1
11	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 603-27	4.2	79
10	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. <i>Atherosclerosis</i> , 2014 , 232, 99-109	3.1	97
9	Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3410-7	5.6	121

8	Non-alcoholic fatty liver disease: diagnosis and investigation. <i>Digestive Diseases</i> , 2014 , 32, 586-96	3.2	8
7	Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 1209-22	6.1	196
6	Drugs and acute porphyrias: reasons for a hazardous relationship. <i>Postgraduate Medicine</i> , 2014 , 126, 108-20	3.7	8
5	Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: chance tetrad or association by necessity?. <i>Digestive and Liver Disease</i> , 2014 , 46, 288-9	3.3	15
4	Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7089-103	5.6	66
3	From NAFLD in clinical practice to answers from guidelines. <i>Journal of Hepatology</i> , 2013 , 59, 859-71	13.4	249
2	Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. <i>Hepatology Research</i> , 2012 , 42, 945	5.1	3
1	Synchronous cryptogenic liver cirrhosis and idiopathic pulmonary fibrosis: a clue to telomere involvement. <i>Hepatology</i> , 2012 , 56, 2001-3	11.2	16